The EndoPredict Result Generator (EPRG) generates the EndoPredict result report (low risk or high risk) and the summary report.

The five-page report provides the risk of developing distant recurrence (0-10 and 5-15 years) and the absolute chemotherapy benefit at 10 years for a woman with ER+, HER2- breast cancer.

Results are summarized by treatment planning stage on the front page. Detailed information is available on the pages that follow

Can chemotherapy be avoided?

Each patient receives an individualized risk of recurrence within years 0-10 after diagnosis: Risk in percent and EPclin Risk Score’s continuous risk curve graphically illustrates the patient’s risk.

With this information, your patients with a low risk of recurrence could be identified and could safely avoid chemotherapy.

What is the benefit from chemotherapy?

Each patient receives an individualized absolute benefit from chemotherapy: Benefit in percent and EPclin Risk Score’s continuous risk curves graphically illustrate the patient’s estimated benefit.

This leads to a confident chemotherapy treatment decision for your patient.

Can the extension of endocrine therapy be avoided?

Each patient receives an individualized risk of recurrence for years 5-15 after diagnosis: Risk in percent and EPclin Risk Score’s continuous risk curve graphically illustrates the patient’s risk.

This information guides treatment decisions regarding endocrine therapy beyond 5 years.